# An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

> **NCT02616211** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 15 (actual)

## Conditions studied

- Adenocarcinoma of Lung
- Lung Neoplasm
- Cancer of Lung
- Lung Cancer
- Pulmonary Cancer
- EGFR Genes
- ALK Genes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02616211
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-10
- **Final completion:** 2019-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616211, "An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02616211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*